INT123802

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.80
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 8
Total Number 8
Disease Relevance 3.54
Pain Relevance 3.01

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Sstr2) plasma membrane (Sstr2) cytoplasm (Sstr2)
signal transducer activity (Sstr2)
Anatomy Link Frequency
Leydig cells 1
Sstr2 (Mus musculus)
Pain Link Frequency Relevance Heat
Somatostatin 127 100.00 Very High Very High Very High
agonist 27 100.00 Very High Very High Very High
anesthesia 11 99.84 Very High Very High Very High
Potency 5 99.28 Very High Very High Very High
Inflammation 29 68.48 Quite High
dexamethasone 2 54.16 Quite High
cytokine 18 28.76 Quite Low
Dopamine 2 13.24 Low Low
antagonist 6 5.00 Very Low Very Low Very Low
Inflammatory response 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Targeted Disruption 45 99.96 Very High Very High Very High
Pituitary Cancer 8 92.76 High High
Anaphylaxis 22 91.24 High High
Nelson Syndrome 3 90.88 High High
Acromegaly 4 87.48 High High
Adenoma 5 75.48 Quite High
Acth-secreting Pituitary Adenoma 7 70.80 Quite High
INFLAMMATION 35 68.48 Quite High
Pituitary Acth Hypersecretion 3 50.00 Quite Low
Rhinitis 1 8.92 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Role of somatostatin receptors on gastric acid secretion in wild-type and somatostatin receptor type 2 knockout mice.
Localization (secretion) of somatostatin receptor type 2 associated with targeted disruption and somatostatin
1) Confidence 0.80 Published 2004 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Title Doc Link 15599710 Disease Relevance 0.55 Pain Relevance 0.46
In wild-type mice, somatostatin-14, SMS 201-995, and the SSTR2-preferential agonist, DC 32-87, inhibited gastrin-stimulated acid secretion with an order of potency SMS 201-995>DC 32-87>somatostatin-14.
Localization (secretion) of SSTR2-preferential associated with agonist, somatostatin and potency
2) Confidence 0.70 Published 2004 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 15599710 Disease Relevance 0.68 Pain Relevance 0.73
Gastrin immunoneutralization or H(2) receptors blockade (cimetidine), but not cholinergic blockade (atropine), reduced the high basal secretion in SSTR2 knockout mice.
Localization (secretion) of SSTR2 associated with targeted disruption
3) Confidence 0.65 Published 2004 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 15599710 Disease Relevance 0.61 Pain Relevance 0.52
We characterized gastric acid secretion in SSTR2 knockout mice, and used preferential somatostatin receptor agonists to assess the relative role of SSTR1, 2, 3, 4, and 5 on gastric acid secretion.
Localization (secretion) of SSTR2 associated with targeted disruption, agonist and somatostatin
4) Confidence 0.61 Published 2004 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 15599710 Disease Relevance 0.33 Pain Relevance 0.38
However, under urethane anesthesia, which releases endogenous somatostatin, SSTR2 knockout mice had a basal secretion 11-15-fold higher than wild-type animals (micromol/10 min:1.40+/-0.09 vs. 0.10+/-0.01, p<0.05).
Localization (releases) of SSTR2 associated with targeted disruption, anesthesia and somatostatin
5) Confidence 0.35 Published 2004 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 15599710 Disease Relevance 0.58 Pain Relevance 0.42
However, our data demonstrates that IgE-mediated activation is associated with reduction of ST2 expression and an increased release of sST2.
Localization (release) of sST2
6) Confidence 0.29 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2914748 Disease Relevance 0.30 Pain Relevance 0.06
This observation could be explained with the lack of glucocorticoid-induced down-regulation of sst2, as mentioned above.52
Localization (regulation) of sst2
7) Confidence 0.27 Published 2010 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2963160 Disease Relevance 0.50 Pain Relevance 0.13
Functional assays showed that the sst2 agonist octreotide inhibited both basal and hCG-stimulated testosterone secretion by testosterone pretreated Leydig cells.
Localization (secretion) of sst2 in Leydig cells associated with agonist
8) Confidence 0.14 Published 2003 Journal Reprod Biol Endocrinol Section Abstract Doc Link PMC151791 Disease Relevance 0 Pain Relevance 0.30

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox